1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,070 | 1,230 | 13:30 | |
| 1,130 | 1,180 | 13:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | NanoViricides: Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution | 162 | ACCESS Newswire | NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC)... ► Artikel lesen | |
| 08.05. | NanoViricides: Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo | 489 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES)... ► Artikel lesen | |
| 05.05. | D.Boral Capital: NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC | 461 | Newsfile | Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 29.04. | Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It | 391 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 14.04. | Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak | 523 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 11.03. | NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company | 813 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that... ► Artikel lesen | |
| 04.03. | Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan | 653 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled "Measles outbreak is call to action for all of us".... ► Artikel lesen | |
| 19.02. | NanoViricides GAAP EPS of -$0.14 | 2 | Seeking Alpha | ||
| 19.02. | NanoViricides, Inc. Has Filed its Quarterly Report | 575 | ACCESS Newswire | Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS Newswire / February 19, 2025 / NanoViricides, Inc. (NYSE... ► Artikel lesen | |
| 14.02. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.02. | NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape | 724 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum... ► Artikel lesen | |
| 29.01. | NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025 | 738 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the... ► Artikel lesen | |
| 27.01. | NanoViricides Engages CRO for Phase II Clinical Trial | 958 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase... ► Artikel lesen | |
| 13.01. | NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 | 536 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 08.01. | NanoViricides: Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals | 706 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are... ► Artikel lesen | |
| 23.12.24 | NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape | 1.944 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential... ► Artikel lesen | |
| 12.12.24 | NANOVIRICIDES, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 15.11.24 | NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID | 661 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September... ► Artikel lesen | |
| 04.11.24 | NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am | 854 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen | |
| 22.10.24 | NanoViricides President Dr. Diwan to Present at the PODD Conference | 498 | ACCESS Newswire | SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that... ► Artikel lesen |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 23,000 | -0,86 % | Formycon-Aktie: Kurs fällt ab (23,90 €) | An der deutschen Börse notiert das Wertpapier von Formycon derzeit ein wenig leichter. Der jüngste Kurs betrug 23,90 Euro. Für die Aktie von Formycon steht gegenwärtig ein Abschlag von 2,65 Prozent... ► Artikel lesen | |
| SOLESENCE | 3,960 | 0,00 % | SOLESENCE, INC. - 10-Q, Quarterly Report | ||
| ONTO INNOVATION | 91,50 | -2,14 % | Onto Innovation: Chancen und Risiken einer dynamischen Aktie | ||
| GAUZY | 8,880 | 0,00 % | Gauzy GAAP EPS of -$0.58, revenue of $22.4M | ||
| VEECO INSTRUMENTS | 19,100 | 0,00 % | Breaking Down Veeco Instruments: 7 Analysts Share Their Views | ||
| NANOFORM FINLAND | 0,942 | -1,57 % | Nanoform Finland Oyj: Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc | Company release
Nanoform Finland Plc
April 15, 2025
14.10 Finnish time / 13.10 Swedish time
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Nanoform Finland... ► Artikel lesen | |
| DOTZ NANO | 0,045 | -3,23 % | XFRA 57N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,049 | +2,49 % | FendX Technologies Inc.: FendX Announces Share Issuance Pursuant to IP License Agreement | Oakville, Ontario--(Newsfile Corp. - May 5, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection... ► Artikel lesen | |
| KOPIN | 1,271 | +1,68 % | KOPIN CORP - 10-Q, Quarterly Report | ||
| OBDUCAT | 0,055 | -8,33 % | NGM MARKET NOTICE: #25-43 Information regarding the last day of trading in paid subscribed shares issued by Obducat AB | ||
| ACACIA RESEARCH | 3,200 | 0,00 % | ACACIA RESEARCH CORP - 10-Q, Quarterly Report | ||
| ADVANCE ZINCTEK | 0,434 | -0,46 % | ADVANCE ZINCTEK LIMITED: Business Update | ||
| LEHNER INVESTMENTS | 0,035 | 0,00 % | EQS-Adhoc: LEHNER INVESTMENTS AG: Sonderprüfung gerichtlich angeordnet | EQS-Ad-hoc: LEHNER INVESTMENTS AG / Schlagwort(e): Rechtssache
LEHNER INVESTMENTS AG: Sonderprüfung gerichtlich angeordnet
04.04.2025 / 18:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| NANOFOCUS | 1,180 | 0,00 % | NanoFocus schließt Kapitalerhöhung ab | Die NanoFocus AG hat die beschlossene Kapitalerhöhung gegen Sach- und Bareinlagen durchgeführt. Insgesamt wurden 6.021.664 neue Aktien zu je 1,00 Euro ausgegeben. Davon gingen 4.276.884 Aktien an die... ► Artikel lesen | |
| RIBER | 2,830 | -1,05 % | Australian National Fabrication Facility orders Riber MBE 412 cluster platform |
Das Unternehmen NANOVIRICIDES INC kann der Branche Nanotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.